Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.
